Modern biopharmaceuticals : (Record no. 12727)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04827cam a2200613Ma 4500 |
| 001 - CONTROL NUMBER | |
| control field | ocn842412695 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20171224114309.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr |n||||||||a |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 110329s2013 gw fo 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | CDX |
| Language of cataloging | eng |
| Description conventions | pn |
| Transcribing agency | CDX |
| Modifying agency | DG1 |
| -- | YDXCP |
| -- | NOC |
| -- | OCLCQ |
| -- | OCLCO |
| -- | OCLCF |
| -- | OCLCQ |
| -- | EBLCP |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783527669417 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 3527669418 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781299448902 |
| Qualifying information | (MyiLibrary) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1299448909 |
| Qualifying information | (MyiLibrary) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Cancelled/invalid ISBN | 9783527322831 |
| Qualifying information | (Cloth) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Cancelled/invalid ISBN | 3527322833 |
| Qualifying information | (Cloth) |
| 029 1# - (OCLC) | |
| OCLC library identifier | AU@ |
| System control number | 000051629414 |
| 029 1# - (OCLC) | |
| OCLC library identifier | CHBIS |
| System control number | 010026923 |
| 029 1# - (OCLC) | |
| OCLC library identifier | CHVBK |
| System control number | 30623761X |
| 029 1# - (OCLC) | |
| OCLC library identifier | DEBBG |
| System control number | BV043395820 |
| 029 1# - (OCLC) | |
| OCLC library identifier | GBVCP |
| System control number | 790207273 |
| 029 1# - (OCLC) | |
| OCLC library identifier | NZ1 |
| System control number | 15340137 |
| 029 1# - (OCLC) | |
| OCLC library identifier | NZ1 |
| System control number | 15905464 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)842412695 |
| 037 ## - SOURCE OF ACQUISITION | |
| Stock number | 476140 |
| Source of stock number/acquisition | MIL |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM301.4 |
| 060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
| Classification number | QV 38 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1/9 |
| Edition number | 22 |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | MAIN |
| 245 00 - TITLE STATEMENT | |
| Title | Modern biopharmaceuticals : |
| Remainder of title | recent success stories / |
| Statement of responsibility, etc | edited by Jorg Knablein. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc | Weinheim : |
| Name of publisher, distributor, etc | Wiley-VCH Verlag GmbH, |
| Date of publication, distribution, etc | 2013. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (450 pages) |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 588 0# - | |
| -- | Print version record. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Related Titles; Title Page; Copyright; Dedication; Foreword by Andreas Busch; Foreword by Günter Stock; Preface; Quotes; List of Contributors; Part I: Modern Biopharmaceuticals: Research is the Best Medicine -- Sanitas Summum Bonus; Chapter 1: Twenty Thousand Years of Biotech -- From "Traditional" to "Modern Biotechnology"; 1.1 Biotechnology -- The Science Creating Life; 1.2 The Inauguration of Biotechnology; 1.3 From "Traditional" to "Modern Biotechnology"; 1.4 A Small Molecule from Bacteria -- A Huge Importance for Mankind; 1.5 Biopharmaceuticals -- The Mainstay of Modern Biotechnology |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 1.6 Transformation of the Pharma Industry Through Biotechnology1.7 Biopharmaceutical Production -- Uncorking Bottlenecks or Wasting Surplus Capacity?; 1.8 Conclusion and Outlook; References; Part II: Modern Biopharmaceutical Development Using Stem Cells, Tissues, and Whole Animals; Chapter 2: Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? -- The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals; 2.1 Introduction; 2.2 Derivation and Growth of hESC; 2.3 Signaling Pathways and Transcription Factors |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.4 Differentiation and Applications of hESC2.5 Patient-Specific Nuclear Transfer Stem Cells; 2.6 Patient-Specific Pluripotent Cells Through Direct Reprogramming of Adult Somatic Cells; 2.7 Concluding Remarks and Outlook; Acknowledgment; References; Chapter 3: Pluripotent Stem Cell-Derived Cardiomyocytes for Industrial and Clinical Applications; 3.1 Introduction; 3.2 Pluripotent Stem Cells; 3.3 High-Yield Differentiation of Pluripotent Stem Cells into Cardiomyocytes; 3.4 Purification of Pluripotent Stem Cell-Derived Cardiomyocytes; 3.5 Cardiomyocytes at an Industrial Scale |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3.6 Utilization of Tissue Engineering Technologies to Advance Cellular Maturity3.7 Concluding Remarks; References; Chapter 4: Industrialization of Functional Mouse Genomics Technologies for Biopharmaceutical Drug Discovery and Development; 4.1 Introduction; 4.2 The Mouse Genetics Story; 4.3 Establishing Inducible Gene Targeting Tools; 4.4 RNAi -- Talking About a Revolution?; 4.5 Further Shortening the Generation Timeline for RNAi Mouse Models; 4.6 Adapting the Mouse Genetics Toolbox for New Applications; References; Part III: Innovative Development Tools for Modern Biopharmaceuticals |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 5: Standardized Solutions for Quantitative and Real-Time RT-PCR to Accelerate Biopharmaceutical Development5.1 Introduction; 5.2 Potential of Real-Time RT-PCR in Biopharmaceutical Development; 5.3 Accurate Gene Expression Analysis Depends on Standardized Preanalytical Steps; 5.4 Accuracy of Real-Time RT-PCR Depends on Efficient cDNA Synthesis; 5.5 Integration of Preanalytical Steps Streamlines Gene Expression Analysis; 5.6 Overview of Methods for Real-Time RT-PCR; 5.7 Developments in Real-Time PCR Instrumentation; 5.8 The Need for Better Standardization of Quantification Methods |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biopharmaceutics. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biopharmaceutics. |
| Source of heading or term | fast |
| -- | (OCoLC)fst00832650 |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Knäblein, Jörg. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Print version: |
| International Standard Book Number | 9781299448902 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://onlinelibrary.wiley.com/book/10.1002/9783527669417 |
| Public note | Wiley Online Library |
| 938 ## - | |
| -- | EBL - Ebook Library |
| -- | EBLB |
| -- | EBL4044490 |
| 938 ## - | |
| -- | Coutts Information Services |
| -- | COUT |
| -- | 25218340 |
| 938 ## - | |
| -- | YBP Library Services |
| -- | YANK |
| -- | 10350843 |
| 994 ## - | |
| -- | 92 |
| -- | DG1 |
No items available.